PCSA Earnings Processa Pharmaceuticals, Inc.
Reported diluted EPS by fiscal period (SEC EDGAR). Chart & overview →
1–18 of 18
| Q1 2026 | 2026-03-31 | -1.29 | 2026-05-07 | 10-Q |
| FY 2025 | 2025-12-31 | -10.36 | 2026-03-18 | 10-K |
| Q3 2025 | 2025-09-30 | -0.41 | 2025-11-06 | 10-Q |
| Q2 2025 | 2025-06-30 | -0.55 | 2025-08-07 | 10-Q |
| Q1 2026 | 2025-03-31 | -7.58 | 2026-05-07 | 10-Q |
| FY 2025 | 2024-12-31 | -96.78 | 2026-03-18 | 10-K |
| Q3 2025 | 2024-09-30 | -3.13 | 2025-11-06 | 10-Q |
| Q2 2025 | 2024-06-30 | -2.11 | 2025-08-07 | 10-Q |
| Q1 2025 | 2024-03-31 | -1.11 | 2025-05-08 | 10-Q |
| FY 2024 | 2023-12-31 | -8.48 | 2025-03-20 | 10-K |
| Q3 2024 | 2023-09-30 | -6.81 | 2024-10-30 | 10-Q |
| Q2 2024 | 2023-06-30 | -5.34 | 2024-08-13 | 10-Q |
| Q1 2024 | 2023-03-31 | -3.53 | 2024-05-10 | 10-Q |
| FY 2023 | 2022-12-31 | -34.05 | 2024-03-29 | 10-K |
| Q3 2023 | 2022-09-30 | -0.90 | 2023-11-13 | 10-Q |
| Q2 2023 | 2022-06-30 | -0.53 | 2023-08-10 | 10-Q |
| FY 2017 | 2017-12-31 | -0.06 | 2018-04-16 | 10-K |
| FY 2017 | 2016-12-31 | -0.07 | 2018-04-16 | 10-K |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Informational only — not financial advice.